

This week in therapeutics

Indication	Target/marker/pathway	Summary	Licensing status	Publication and contact information
Infectious disease				
Bacterial infection	UDP-3-O-[3-hydroxymyristoyl] N-acetylglucosamine deacetylase (LpxC)	<i>In vitro</i> and mouse studies identified hydroxamic acid-based LpxC inhibitors that could help treat Gram-negative bacterial infections. <i>In vitro</i> , the compounds inhibited LpxC at low nanomolar IC ₅₀ values. In a mouse model of systemic <i>Pseudomonas aeruginosa</i> infection, a lead compound decreased bacterial growth compared with no treatment. Next steps include further optimization of lead LpxC inhibitors.	Patent application filed; licensing status undisclosed	Brown, M.F. <i>et al.</i> <i>J. Med. Chem.</i> ; published online Dec. 18, 2011; doi:10.1021/jm2014748 Contact: Matthew F. Brown, Pfizer Global Research and Development, Groton, Conn. e-mail: matthew.f.brown@pfizer.com
SciBX 5(3); doi:10.1038/scibx.2012.75 Published online Jan. 19, 2012				